NIH Awards Grant to Avexegen to Advance IBD Investigational Therapy

NIH Awards Grant to Avexegen to Advance IBD Investigational Therapy
Avexegen Therapeutics has been awarded a $225,000 grant from the National Institutes of Health (NIH) to advance the clinical development of NRG-4 (Neuregulin-4), the company’s lead investigational drug candidate for the treatment of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. The grant, awarded under the NIH’s Small Business Innovation Research Program (SBIR),

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *